Serenex, a privately held biotech company that develops chemoproteomic technologies has named Bert Pronk as director of biology.
Pronk joins Serenex from atugen AG, where he served as director of research and business development. At the German company’s Boulder, CO facility, he managed all North American customer collaborations, and supported internal R&D projects in various disease areas.
Before joining atugen, Pronk served in various scientific positions at Chiron Corporation, most recently as senior scientist, target development and kinase drug discovery. He also has authored numerous scientific papers and has presented his work at various scientific meetings.
“We are excited to have Dr. Pronk join Serenex,” said Richard Kent, president and chief executive officer of the Durham-based company. “His expertise in target discovery and validation combined with his experience in kinase drug discovery complements our already experienced scientific team in our declared therapeutic areas of oncology and inflammation.”